Risk Factors of Cardiotoxicity in Patients with Breast Cancer After Sequential Trastuzumab Therapy with Anthracyclines

ZHU Xiaoli; LYU Chen; DU Xueting; JIAO Jiaxun; GAO Lingna; SUN Xia; MA Hongfang

doi:10.14009/j.issn.1672-2124.2022.03.019

您当前的位置：

首页 >

文章列表页 >

Risk Factors of Cardiotoxicity in Patients with Breast Cancer After Sequential Trastuzumab Therapy with Anthracyclines

更新时间：2022-10-08

- Risk Factors of Cardiotoxicity in Patients with Breast Cancer After Sequential Trastuzumab Therapy with Anthracyclines
- Vol. 22, Issue 3, Pages: 338-341(2022)
- 作者机构：
  
  1. 衡水市人民医院药学部
  2. 衡水市人民医院肿瘤内科
  3. 衡水市人民医院骨肿瘤科
  4. 衡水市人民医院超声科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.03.019
  CLC： R737.9
- Published：2022，
扫描看全文
ZHU Xiaoli, LYU Chen, DU Xueting, et al. Risk Factors of Cardiotoxicity in Patients with Breast Cancer After Sequential Trastuzumab Therapy with Anthracyclines. [J]. 22(3):338-341(2022)
DOI：

ZHU Xiaoli, LYU Chen, DU Xueting, et al. Risk Factors of Cardiotoxicity in Patients with Breast Cancer After Sequential Trastuzumab Therapy with Anthracyclines. [J]. 22(3):338-341(2022) DOI： 10.14009/j.issn.1672-2124.2022.03.019.

摘要

目的：探讨蒽环类药物序贯曲妥珠单抗治疗导致乳腺癌患者心脏毒性的相关危险因素。方法：选择2017年4月至2020年1月该院采用蒽环类药物序贯曲妥珠单抗治疗的乳腺癌患者169例，观察其心脏毒性发生情况，分为心脏毒性组与非心脏毒性组。记录并分析两组患者的年龄、体重指数、肿瘤分期、高血压史、糖尿病史、高脂血症史、联合放疗和蒽环类药物种类等因素的差异。通过Logistic回归，分析蒽环类药物序贯曲妥珠单抗治疗后乳腺癌患者出现心脏毒性的危险因素。结果：169例采用蒽环类药物序贯曲妥珠单抗治疗的乳腺癌患者中，发生心脏毒性患者57例，心脏毒性发生率为33.73%。心脏毒性组与非心脏毒性组患者在高脂血症史、联合放疗和蒽环类药物种类方面的差异均有统计学意义(P<0.05)。进一步分析发现，相对于无高脂血症的患者，高脂血症患者发生心脏毒性的风险增加(OR=5.068

95%CI=2.209～11.628);相对于无联合放疗的患者，左胸放疗患者发生心脏毒性的风险增加(OR=3.734

95%CI=1.448～9.628);相对于使用表柔比星治疗的患者，使用吡柔比星治疗的患者发生心脏毒性的风险更小(OR=0.407

95%CI=0.182～0.911)。结论：采用蒽环类药物序贯曲妥珠单抗治疗的乳腺癌患者心脏毒性发生率较高。表柔比星治疗、高脂血症史和左胸放疗史是蒽环类药物序贯曲妥珠单抗治疗导致乳腺癌患者心脏毒性的独立危险因素。

Abstract

OBJECTIVE: To probe into the related risk factors of cardiotoxicity in patients with breast cancer after sequential trastuzumab therapy with anthracyclines. METHODS: Totally 169 patients with breast cancer undergoing sequential trastuzumab therapy with anthracyclines in this hospital from Apr. 2017 to Jan. 2020 were extracted to be divided into the cardiotoxicity group and the non-cardiotoxicity group according to the incidence of cardiotoxicity. The age

body mass index

tumor stage

history of hypertension

history of diabetes

history of hyperlipidemia

combined radiotherapy

categories of anthracyclines and other factors of two groups of patients were recorded and analyzed. Risk factors of cardiotoxicity in patients with breast cancer after sequential trastuzumab therapy with anthracyclines were analyzed by logistic regression. RESULTS: Among 169 patients with breast cancer after sequential trastuzumab therapy with anthracyclines

57 patients developed cardiotoxicity

with the incidence of 33.73%. There were statistically significant differences between the cardiotoxicity group and the non-cardiotoxicity group in the history of hyperlipidemia

combined radiotherapy and categories of anthracyclines（P<0.05）. Further analysis showed that patients with hyperlipidemia had an increased risk of cardiotoxicity compared with those without hyperlipidemia（OR=5.068

95%CI=2.209-11.628）. Patients treated with left thoracic radiotherapy had an increased risk of cardiotoxicity compared with those without combined radiotherapy（OR=3.734

95%CI=1.448-9.628）. Compared with patients received epirubicin

patients received pirarubicin had a lower risk of cardiotoxicity（OR=0.407

95%CI=0.182-0.911）. CONCLUSIONS: The incidence of cardiotoxicity in patients with breast cancer after sequential trastuzumab therapy with anthracyclines is higher. Treatment with epirubicin

history of hyperlipidemia and history of left thoracic radiotherapy are independent risk factors for cardiotoxicity in patients with breast cancer after sequential trastuzumab therapy with anthracyclines.

关键词

蒽环类药物曲妥珠单抗心脏毒性乳腺癌危险因素分析

Keywords

AnthracyclineTrastuzumabCardiotoxicityBreast cancerAnalysis of risk factors

references

查看原文

Views

122

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Continuous Intravenous Infusion of Dexmedetomidine Combined with Oxycodone on Inflammatory Response and Immune Function in Patients with Breast Cancer During General Anesthesia

Comparative Study on Different Administration Method of Propofol in Breast Cancer Surgery

Effects of Danshen Ligustrazine Injection Combined with EC-T Regimen on Short-Term Efficacy, Immune Function and Quality of Life in Patients with Breast Cancer After Surgery

Molecular Mechanism of Iphigenia Indica in the Treatment of Breast Cancer Based on Network Pharmacology

Effects of Apatinib on Tumor Inhibition Rate and Tumor Cell Apoptosis in Breast Cancer Mouse Model by Regulating Extracellular Regulated Kinase 1/2 Pathway

Related Author

LIU Xiaomei

NING Lijuan

GAN Zuren

WU Jiaying

CAI Qinfeng

ZHOU Caishan

LI Yanli

GAO Yang

Related Institution

Dept.of Anesthesiology,Sixth Medical Center of Chinese PLA General Hospital

Dept.of Anesthesiology, Haikou Hospital of Traditional Chinese Medicine

Dept. of General Surgery, Qinhuangdao the First Hospital

Dept. of Breast Surgery, Zhejiang Cancer Hospital

Dept. of Breast Surgery, Qinhuangdao the First Hospital

⁰